scispace - formally typeset
C

Carlos J. V. Simões

Researcher at University of Coimbra

Publications -  25
Citations -  161

Carlos J. V. Simões is an academic researcher from University of Coimbra. The author has contributed to research in topics: Transthyretin & Medicine. The author has an hindex of 6, co-authored 18 publications receiving 107 citations.

Papers
More filters
Journal ArticleDOI

Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: insights from molecular dynamics simulations.

TL;DR: Results clearly show that, in comparison with WT, L55P‐TTR does present a much higher probability of forming transient conformations compatible with aggregation and amyloid formation.
Journal ArticleDOI

Assessing the influence of electrostatic schemes on molecular dynamics simulations of secondary structure forming peptides

TL;DR: In this paper, the authors evaluated the influence of different electrostatic schemes on the results of molecular dynamics simulations and concluded that PME and RF schemes perform better in maintaining the structure close to the native one for the β-sheet peptide beta3, in which long range contacts are mostly responsible for the definition of the native structure.
Journal ArticleDOI

Toward the Discovery of Functional Transthyretin Amyloid Inhibitors: Application of Virtual Screening Methods

TL;DR: This study presents a benchmark of four protein- and ligand-based virtual screening (VS) methods for identifying novel TTR stabilizer molecules and predicts that the top-scoring molecules possess distinctive features from the known TTR binders, holding better solubility, fraction of halogen atoms, and binding affinity profiles.
Journal ArticleDOI

A novel bis-furan scaffold for transthyretin stabilization and amyloid inhibition

TL;DR: The design and synthesis of a novel bis-furan scaffold tailored for high efficiency at inhibiting transthyretin amyloid formation is reported, and results show that the discovered compounds are more efficient inhibitors of amyloids formation than tafamidis, a drug currently used in the treatment of familialAmyloid polyneuropathy (FAP).
Journal ArticleDOI

Synthesis and structure-activity relationships of new chiral spiro-β-lactams highly active against HIV-1 and Plasmodium

TL;DR: In this paper, the synthesis and antimicrobial activity of new spiro-β-lactams was reported based on the structural modulation of two previously identified lead spiropenicillanates with dual activity against HIV and Plasmodium.